摘要

Circulating blood cells, and cell-derived microvesicles, are emerging as pragmatic delivery systems that can smartly complement the already existing nanotherapeutic platforms evaluated to treat or diagnose diseases. The valuable distinctive features of circulatory cells over synthetic nanocarriers encompass their biological origin which confers immune transparence, known biodegradability, high drug loading, relatively long half-life and a targeting capacity associated with their physiological surface functionality. Absence of nuclei in red blood cells and platelets provides further rationale for their use as cargo vehicles for nucleotoxic agents. Ongoing developments in cell-based and cell-inspired nanotherapies can move drug delivery into reachable frontiers and exhibit high potentiality for translatability into clinical use.
原文英語
頁(從 - 到)934-943
頁數10
期刊Drug Discovery Today
23
發行號5
DOIs
出版狀態已發佈 - 五月 1 2018

指紋

Artificial Cells
Pharmaceutical Preparations
Half-Life
Blood Cells
Blood Platelets
Erythrocytes

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

引用此文

Circulatory-cell-mediated nanotherapeutic approaches in disease targeting. / Burnouf, Thierry; Burnouf, Pierre Alain; Wu, Yu Wen; Chuang, Er Yuan; Lu, Long Sheng; Goubran, Hadi.

於: Drug Discovery Today, 卷 23, 編號 5, 01.05.2018, p. 934-943.

研究成果: 雜誌貢獻簡短的問卷調查

Burnouf, Thierry ; Burnouf, Pierre Alain ; Wu, Yu Wen ; Chuang, Er Yuan ; Lu, Long Sheng ; Goubran, Hadi. / Circulatory-cell-mediated nanotherapeutic approaches in disease targeting. 於: Drug Discovery Today. 2018 ; 卷 23, 編號 5. 頁 934-943.
@article{b3eed12242fd4101931ccb4236eec09b,
title = "Circulatory-cell-mediated nanotherapeutic approaches in disease targeting",
abstract = "Circulating blood cells, and cell-derived microvesicles, are emerging as pragmatic delivery systems that can smartly complement the already existing nanotherapeutic platforms evaluated to treat or diagnose diseases. The valuable distinctive features of circulatory cells over synthetic nanocarriers encompass their biological origin which confers immune transparence, known biodegradability, high drug loading, relatively long half-life and a targeting capacity associated with their physiological surface functionality. Absence of nuclei in red blood cells and platelets provides further rationale for their use as cargo vehicles for nucleotoxic agents. Ongoing developments in cell-based and cell-inspired nanotherapies can move drug delivery into reachable frontiers and exhibit high potentiality for translatability into clinical use.",
author = "Thierry Burnouf and Burnouf, {Pierre Alain} and Wu, {Yu Wen} and Chuang, {Er Yuan} and Lu, {Long Sheng} and Hadi Goubran",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.drudis.2017.08.012",
language = "English",
volume = "23",
pages = "934--943",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Circulatory-cell-mediated nanotherapeutic approaches in disease targeting

AU - Burnouf, Thierry

AU - Burnouf, Pierre Alain

AU - Wu, Yu Wen

AU - Chuang, Er Yuan

AU - Lu, Long Sheng

AU - Goubran, Hadi

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Circulating blood cells, and cell-derived microvesicles, are emerging as pragmatic delivery systems that can smartly complement the already existing nanotherapeutic platforms evaluated to treat or diagnose diseases. The valuable distinctive features of circulatory cells over synthetic nanocarriers encompass their biological origin which confers immune transparence, known biodegradability, high drug loading, relatively long half-life and a targeting capacity associated with their physiological surface functionality. Absence of nuclei in red blood cells and platelets provides further rationale for their use as cargo vehicles for nucleotoxic agents. Ongoing developments in cell-based and cell-inspired nanotherapies can move drug delivery into reachable frontiers and exhibit high potentiality for translatability into clinical use.

AB - Circulating blood cells, and cell-derived microvesicles, are emerging as pragmatic delivery systems that can smartly complement the already existing nanotherapeutic platforms evaluated to treat or diagnose diseases. The valuable distinctive features of circulatory cells over synthetic nanocarriers encompass their biological origin which confers immune transparence, known biodegradability, high drug loading, relatively long half-life and a targeting capacity associated with their physiological surface functionality. Absence of nuclei in red blood cells and platelets provides further rationale for their use as cargo vehicles for nucleotoxic agents. Ongoing developments in cell-based and cell-inspired nanotherapies can move drug delivery into reachable frontiers and exhibit high potentiality for translatability into clinical use.

UR - http://www.scopus.com/inward/record.url?scp=85029686136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029686136&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2017.08.012

DO - 10.1016/j.drudis.2017.08.012

M3 - Short survey

VL - 23

SP - 934

EP - 943

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 5

ER -